Suppr超能文献

苏拉明对介导豚鼠输精管和膀胱收缩的P2-嘌呤受体的不同作用。

Differential effects of suramin on P2-purinoceptors mediating contraction of the guinea-pig vas deferens and urinary bladder.

作者信息

Bailey S J, Hourani S M

机构信息

Receptors & Cellular Regulation Research Group, School of Biological Sciences, University of Surrey, Guildford, Surrey.

出版信息

Br J Pharmacol. 1994 May;112(1):219-25. doi: 10.1111/j.1476-5381.1994.tb13055.x.

Abstract
  1. The effect of the P2-purinoceptor antagonist, suramin, was investigated on contractions of the guinea-pig vas deferens and urinary bladder induced by adenosine 5'-triphosphate (ATP) and by the other naturally occurring nucleoside triphosphates. 2. ATP, guanosine 5'-triphosphate (GTP), cytidine 5'-triphosphate (CTP), inosine 5'-triphosphate (ITP) and uridine 5'-triphosphate (UTP) (0.1-500 microM) each contracted both the guinea-pig bladder and the guinea-pig vas deferens. In the vas deferens the order of potency of the nucleotides was ATP >> CTP > GTP > or = UTP = ITP, and in the bladder it was ATP >> CTP = GTP > UTP = ITP, although maximal responses to these agonists were not achieved in either tissue. 3. Suramin (30 microM-1 mM) dose-dependently inhibited ATP-induced contractions of the bladder in an apparently non-competitive manner, causing a reduction in the slope of the concentration-response curve to ATP. In contrast, suramin (5 microM-1 mM) had little inhibitory effect on ATP-induced contractions of the vas deferens, and indeed at concentrations of 100 microM and above markedly potentiated high concentrations of ATP (100-500 microM). The contractions induced by CTP, GTP, UTP and ITP (1-500 microM) were, however, abolished by suramin (1 mM) in each tissue. 4. Desensitization of the P2X purinoceptors in the guinea-pig vas deferens with adenosine 5'-alpha,beta-methylenetriphosphonate (AMPCPP) (300 microM) abolished contractions induced by ATP (1 microM-1 mM) in the absence of suramin. However, the contractions induced in the presence of suramin were unaffected by prior desensitization, indicating that they were not mediated by P2X-purinoceptors.5. ATP (100 MicroM) was dephosphorylated by both isolated tissue preparations under the conditions of these experiments, breakdown products being detectable after 2 min, with the major breakdown product in the bladder being inosine whereas that in the vas deferens was adenosine. Approximately 35% of the ATP remained intact after incubation for 30 min with the bladder, and approximately 45% remained after incubation for 30 min with the vas deferens. In each tissue this degradation was inhibited by suramin (1 mM), so that after incubation of ATP (100 MicroM) in the presence of suramin for 30 min,approximately 50% remained in the case of the bladder and approximately 65% remained in the vas deferens. However, inhibition of the production of the inhibitory agonist, adenosine by suramin did not appear to be responsible for the potentiation observed in the vas deferens, as the PI-purinoceptor antagonist 8-sulphophenyltheophylline (100 MicroM) did not reduce this potentiation.6. Chelation of divalent cations did not appear to account for the enhancement by suramin of ATP-induced contractions of the vas deferens, as the enhancement was still observed when Mg2+ was omitted from the buffer or when its concentration (normally 1.2 mM) was increased ten fold to 12 mM,or when the concentration of Ca2+ (normally 2.5 mM) was reduced to 0.83 mM. Even in the absence of Mg2+ and with the Ca2+ concentration reduced to 0.83 mM, no inhibition by suramin (1 mM) of ATP-induced contractions was observed.7. The most likely explanation for the potentiation by suramin of the ATP-induced contractions of the vas deferens is the co-existence of inhibitory P2Y-purinoceptors. However, no consistent relaxations to ATP (1-100 MicroM) or to the more potent P2Y-purinoceptor agonist 2-methylthioadenosine 5'-triphosphate(2-MeSATP) (0.01-100 MicroM) could be detected in the vas deferens precontracted with KCl (35 mM), even after desensitization of P2x-purinoceptors with AMPCPP (300 MicroM). Similarly, ATP (1-100 MicroM) or 2-MeSATP (0.01-1100 MicroM) added before KCI (35 mM), carbachol (10 JM) or noradrenaline (10 MicroM) did not reduce subsequent contractions to these agents.8. The differential effect of suramin on the contractions induced by ATP in the bladder and the vas deferens was unexpected, and shows that the receptor populations by which ATP acts in these tissues may not be identical. The failure of suramin to inhibit responses to ATP in the vas deferens suggests that this tissue, in addition to possessing P2x-purinoceptors may also possess a suramin-insensitive contractile ATP receptor revealed in the presence of suramin.
摘要
  1. 研究了P2嘌呤受体拮抗剂苏拉明对豚鼠输精管和膀胱由5'-三磷酸腺苷(ATP)及其他天然存在的核苷三磷酸诱导的收缩作用。2. ATP、5'-三磷酸鸟苷(GTP)、5'-三磷酸胞苷(CTP)、5'-三磷酸肌苷(ITP)和5'-三磷酸尿苷(UTP)(0.1 - 500微摩尔)均可使豚鼠膀胱和输精管收缩。在输精管中,核苷酸的效力顺序为ATP >> CTP > GTP > 或 = UTP = ITP,在膀胱中为ATP >> CTP = GTP > UTP = ITP,尽管在两种组织中均未达到对这些激动剂的最大反应。3. 苏拉明(30微摩尔 - 1毫摩尔)以明显非竞争性方式剂量依赖性抑制ATP诱导的膀胱收缩,导致ATP浓度 - 反应曲线斜率降低。相比之下,苏拉明(5微摩尔 - 1毫摩尔)对ATP诱导的输精管收缩几乎没有抑制作用,实际上在100微摩尔及以上浓度时,可显著增强高浓度ATP(100 - 500微摩尔)的作用。然而,CTP、GTP、UTP和ITP(1 - 500微摩尔)诱导的收缩在每个组织中均被1毫摩尔苏拉明消除。4. 用5'-α,β-亚甲基三磷酸腺苷(AMPCPP)(300微摩尔)使豚鼠输精管中的P2X嘌呤受体脱敏,在无苏拉明的情况下可消除ATP(1微摩尔 - 1毫摩尔)诱导的收缩。然而,在苏拉明存在下诱导的收缩不受预先脱敏的影响,表明它们不是由P2X嘌呤受体介导的。5. 在这些实验条件下,两种离体组织制剂均可使ATP(100微摩尔)去磷酸化,2分钟后可检测到分解产物,膀胱中的主要分解产物是肌苷,而输精管中的是腺苷。与膀胱孵育30分钟后,约35%的ATP保持完整,与输精管孵育30分钟后约45%保持完整。在每个组织中,这种降解均被1毫摩尔苏拉明抑制,因此在苏拉明存在下将ATP(100微摩尔)孵育30分钟后,膀胱中约50%保持完整,输精管中约65%保持完整。然而,苏拉明对抑制性激动剂腺苷产生的抑制作用似乎不是输精管中观察到的增强作用的原因,因为P1嘌呤受体拮抗剂8 - 磺基苯基茶碱(100微摩尔)并未降低这种增强作用。6. 二价阳离子的螯合似乎不能解释苏拉明对ATP诱导的输精管收缩的增强作用,因为当缓冲液中省略Mg2+或其浓度(通常为1.2毫摩尔)增加10倍至12毫摩尔时,或当Ca2+浓度(通常为2.5毫摩尔)降至0.83毫摩尔时,仍可观察到增强作用。即使在无Mg2+且Ca2+浓度降至0.83毫摩尔的情况下,也未观察到1毫摩尔苏拉明对ATP诱导的收缩的抑制作用。7. 苏拉明对ATP诱导的输精管收缩的增强作用最可能的解释是抑制性P2Y嘌呤受体的共存。然而,在预先用KCl(35毫摩尔)预收缩的输精管中,即使在用AMPCPP(300微摩尔)使P2x嘌呤受体脱敏后,也未检测到对ATP(1 - 100微摩尔)或更有效的P2Y嘌呤受体激动剂2 - 甲硫基腺苷5'-三磷酸(2 - MeSATP)(0.01 - 100微摩尔)的一致舒张作用。同样,在加入KCI(35毫摩尔)之前加入ATP(1 - 100微摩尔)或2 - MeSATP(0.01 - 1100微摩尔),卡巴胆碱(10微摩尔)或去甲肾上腺素(10微摩尔)不会降低随后对这些药物的收缩反应。8. 苏拉明对膀胱和输精管中ATP诱导的收缩的不同作用出乎意料,表明ATP在这些组织中起作用的受体群体可能不同。苏拉明未能抑制输精管对ATP的反应表明,该组织除了具有P2x嘌呤受体外,在苏拉明存在时还可能具有对苏拉明不敏感的收缩性ATP受体。

相似文献

引用本文的文献

5
New insights on P2X purinoceptors.P2X嘌呤受体的新见解。
Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;352(6):585-96. doi: 10.1007/BF00171316.

本文引用的文献

7
Studies on the stereoselectivity of the P2-purinoceptor.P2嘌呤受体的立体选择性研究。
Br J Pharmacol. 1983 Aug;79(4):907-13. doi: 10.1111/j.1476-5381.1983.tb10535.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验